mAbxience and OncoPrecision Announce Manufacturing and Investment Agreement for OncoPrecision's ADC Candidate ONC001
<p>MADRID, Nov. 18, 2026 /PRNewswire/ -- mAbxience, a wholly owned company of Fresenius SE & Co. KGaA, and OncoPrecision, a biotechnology company pioneering first-in-class precision therapies for hard-to-treat cancers through the integration of patient-derived biology and AI, headquartered...</p>
Read original article ↗
Related Articles
Les représentants commerciaux et les responsables des relations médicales peuvent lancer ACTO CxZone en un clic depuis l
Sales reps and MSLs can launch ACTO CxZone with one click from their planning screens, practice with an HCP avatar groun
Vertriebsmitarbeiter und MSLs können ACTO CxZone mit einem Klick von ihren Planungsbildschirmen aus starten, mit einem H
Gopuff Joins the Swish Network to Expand Targeted, Measurable Product Sampling
Partnership gives brands more ways to reach high-potential customers through Gopuff, with the flexibility to activate ca